Company Profile
CG Oncology, Inc. Stock Price, News & Analysis
- Ticker:
- CGON
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
74.85 USD (+3.36%)
Close
Last updated: August 6, 2026
4.9B USD
Market cap
Why the stock is moving
Following the latest company update, “CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates”, CGON closed up 3.36% at $74.85 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Bladder-Cancer Immunotherapy
CG Oncology develops oncolytic immunotherapies for bladder cancer. Its lead candidate is administered directly into the bladder to selectively replicate in tumor cells and stimulate an antitumor immune response.
Cretostimogene Grenadenorepvec
Cretostimogene has been studied across more than 600 patients with non-muscle-invasive bladder cancer. Development spans BCG-unresponsive high-risk disease, BCG-exposed disease and intermediate-risk settings.
BCG-Unresponsive Registrational Program
CG Oncology is preparing a BLA based on cretostimogene monotherapy in high-risk, BCG-unresponsive disease, the candidate's initial planned regulatory indication.
Intermediate-Risk Disease
The Phase 3 PIVOT-006 study evaluates cretostimogene as an adjuvant monotherapy in intermediate-risk non-muscle-invasive bladder cancer.
Combination Development
The CORE-008 program evaluates cretostimogene with gemcitabine in BCG-exposed and BCG-unresponsive high-risk disease, broadening the candidate across treatment settings.
Future catalysts
Topline Phase 3 PIVOT-006 data in intermediate-risk NMIBC in the first half of 2026.
Initial Phase 2 CORE-008 Cohort CX data for cretostimogene plus gemcitabine at AUA 2026.
Completion of the BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC in the fourth quarter of 2026.
Recent news
- 01
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
Source: CG Oncology, Inc.
- 02
- 03
CG Oncology to Present at Upcoming Investor Conferences in June
Source: CG Oncology, Inc.
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of CG Oncology, Inc. (CGON)?
CG Oncology, Inc. (CGON) most recently closed at 74.85 USD, a +3.36% move versus the previous session.
What is the market cap of CG Oncology, Inc. (CGON)?
CG Oncology, Inc. currently has a market capitalization of 4.9B USD on BioPharmSignal.
What does CG Oncology, Inc. do?
Bladder-Cancer Immunotherapy CG Oncology develops oncolytic immunotherapies for bladder cancer. Its lead candidate is administered directly into the bladder to selectively replicate in tumor cells and stimulate an antitumor immune response. Cretostimogene Grenadenorepvec Cretostimogene has been studied across more than 600 patients with non-muscle-invasive...
On which exchange is CGON stock listed?
CG Oncology, Inc. (CGON) is associated with NASDAQ, United States, Biopharma.
What is PIVOT-006?
Topline Phase 3 PIVOT-006 data in intermediate-risk NMIBC in the first half of 2026.
Which conditions is CG Oncology, Inc. targeting with PIVOT-006?
CG Oncology, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does CG Oncology, Inc. describe recent progress with PIVOT-006?
Topline Phase 3 PIVOT-006 data in intermediate-risk NMIBC in the first half of 2026.
What is CORE-008?
Combination Development The CORE-008 program evaluates cretostimogene with gemcitabine in BCG-exposed and BCG-unresponsive high-risk disease, broadening the candidate across treatment settings.